1,7-异喹啉二胺 | 244219-96-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 1,7-异喹啉二胺
• 英文名称: 1,7-isoquinolinediamine
• 英文别名: 1,7-diaminoisoquinoline；Isoquinoline-1,7-diamine
• CAS: 244219-96-3
• 化学式: C₉H₉N₃
• mdl: MFCD18802667
• 分子量: 159.191
• InChiKey: PUIYPHIFMLGHFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,7-异喹啉二胺 在 盐酸 、 sodium cyanoborohydride 作用下， 以 乙醇 为溶剂， 生成 7-N-benzylisoquinoline-1,7-diamine;hydrochloride
  参考文献：
  名称：

  In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones

  摘要：

  A series of 1,7-diaminoisoquinolinamines, that are expected to mediate antimalarial activity by the same mechanism employed by the chalcones, were produced. Six 7-benzylamino-1-isoquinolinamines were found to be submicromolar inhibitors in vitro of drug-resistant Plasmodium falciparum, with the best possessing activity comparable to chloroquine. Despite being developed from a lead that is a DHFR inhibitor, these compounds do not mediate their antimalarial effects by inhibition of DHFR. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.11.099
• 作为产物：
  描述：

  7-硝基-1,2,3,4-四氢异喹啉盐酸盐 在 potassium nitrososulfonate 、 10% palladium on activated charcoal 、 氢气 、 sodium carbonate 、 对甲苯磺酰氯 、 间氯过氧苯甲酸 作用下， 以 吡啶 、 水 为溶剂， 生成 1,7-异喹啉二胺
  参考文献：
  名称：

  In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones

  摘要：

  A series of 1,7-diaminoisoquinolinamines, that are expected to mediate antimalarial activity by the same mechanism employed by the chalcones, were produced. Six 7-benzylamino-1-isoquinolinamines were found to be submicromolar inhibitors in vitro of drug-resistant Plasmodium falciparum, with the best possessing activity comparable to chloroquine. Despite being developed from a lead that is a DHFR inhibitor, these compounds do not mediate their antimalarial effects by inhibition of DHFR. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.11.099

文献信息

• Synthesis and antimalarial activity of 7-benzylamino-1-isoquinolinamines
  作者：Clare E. Gutteridge、Marshall M. Hoffman、Apurba K. Bhattacharjee、Lucia Gerena

  DOI：10.1002/jhet.5570440319

  日期：2007.5

  suggests that 7-benzylamino-1-isoquinolinamines should mediate antimalarial effects by a mechanism distinct from that employed by existing antimalarial drugs. A series of these compounds was prepared in seven synthetic steps, via reductive amination of 1,7-isoquinolinediamine. In vitro efficacy testing of the novel compounds against Plasmodium falciparum revealed them to be potent antimalarial agents.

  计算机模型表明7-苄基氨基-1-异喹啉胺应通过不同于现有抗疟药所采用的机制来介导抗疟作用。通过1,7-异喹啉二胺的还原胺化反应，在七个合成步骤中制备了一系列这些化合物。新型化合物对恶性疟原虫的体外功效测试表明，它们是有效的抗疟药。
• Amide derivatives and nociceptin antagonists
  申请人：Japan Tobacco Inc.

  公开号：US06410561B1

  公开（公告）日：2002-06-25

  The present invention relates to a compound of the formula [1′] wherein R2 is lower alkyl optionally substituted by hydroxy, amino and the like, ring B is phenyl, thienyl and the like, E is a single bond, —O—, —S— and the like, ring G is aryl, heterocyclic group and the like, R5 is halogen atom, hydroxy, lower alkyl optionally substituted by halogen atom etc., and the like, t is 0 or an integer of 1 to 5, when t is an integer of 2 to 5, each R5 may be the same or different, m is 0 or an integer of 1 to 8, and n is 0 or an integer of 1 to 4, and a nociceptin antagonist containing compound [1′] as an active ingredient. The compound [1′] shows, due to nociceptin antagonistic action, analgesic effect against sharp pain such as postoperative pain and the like. The present invention also relates to the use of certain amide derivative inclusive of compound [1′] as a nociceptin antagonist or analgesic.

  本发明涉及一种化合物的公式为[1′]，其中R2是可选择地由羟基、氨基等取代的较低烷基，环B是苯基、噻吩基等，E是单键，—O—，—S—等，环G是芳基、杂环基等，R5是卤原子、羟基、可选择地由卤原子等取代的较低烷基等，t为0或1至5的整数，当t为2至5的整数时，每个R5可以相同或不同，m为0或1至8的整数，n为0或1至4的整数，以及包含化合物[1′]作为活性成分的一种痛觉受体拮抗剂。该化合物[1′]由于痛觉受体拮抗作用，对于术后疼痛等剧痛具有镇痛效果。本发明还涉及某些酰胺衍生物的使用，包括化合物[1′]作为痛觉受体拮抗剂或镇痛剂。
• AMIDE DERIVATIVES AND NOCICEPTIN ANTAGONISTS
  申请人：Japan Tobacco Inc.

  公开号：EP1072263A1

  公开（公告）日：2001-01-31

  The present invention relates to a compound of the formula [1' ] wherein R2 is lower alkyl optionally substituted by hydroxy, amino and the like, ring B is phenyl, thienyl and the like, E is a single bond, -O-,-S- and the like, ring G is aryl, heterocyclic group and the like, R5 is halogen atom, hydroxy, lower alkyl optionally substituted by halogen atom etc., and the like, t is 0 or an integer of 1 to 5, when t is an integer of 2 to 5, each R5 may be the same or different, m is 0 or an integer of 1 to 8, and n is 0 or an integer of 1 to 4, and a nociceptin antagonist containing compound [1' ] as an active ingredient The compound [1' ] shows, due to nociceptin antagonistic action, analgesic effect against sharp pain such as postoperative pain and the like. The present invention also relates to the use of certain amide derivative inclusive of compound [1' ] as a nociceptin antagonist or analgesic.

  本发明涉及一种式 [1' ]的化合物。 其中 R2 是任选被羟基、氨基等取代的低级烷基，环 B 是苯基、噻吩基等，E 是单键、-O-、-S- 等，环 G 是芳基、杂环基等，R5 是卤素原子、羟基、任选被卤素原子等取代的低级烷基，t 是 0 或 1 至 5 的整数，当 t 是 2 至 5 的整数时，每个 R5 可以是相同的、等，t 为 0 或 1 至 5 的整数，当 t 为 2 至 5 的整数时，每个 R5 可以相同或不同，m 为 0 或 1 至 8 的整数，n 为 0 或 1 至 4 的整数，以及含有化合物[1']作为活性成分的痛觉素拮抗剂。本发明还涉及包含化合物[1' ]的某些酰胺衍生物作为痛觉素拮抗剂或镇痛剂的用途。
• SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS
  申请人：BioCryst Pharmaceuticals, Inc.

  公开号：EP3828173A1

  公开（公告）日：2021-06-02

  Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention and the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

  公开了本文所述的式 (I) 化合物及其药学上可接受的盐类。这些化合物是血浆卡立克雷因的抑制剂。还提供了包含至少一种本发明化合物的药物组合物，以及涉及使用本发明化合物和组合物、治疗和预防以不需要的血浆卡利克雷因活性为特征的疾病和病症的方法。
• Fragment based search for small molecule inhibitors of HIV-1 Tat-TAR
  作者：Mirco Zeiger、Sebastian Stark、Elisabeth Kalden、Bettina Ackermann、Jan Ferner、Ute Scheffer、Fatemeh Shoja-Bazargani、Veysel Erdel、Harald Schwalbe、Michael W. Göbel

  DOI：10.1016/j.bmcl.2014.11.004

  日期：2014.12

  Basic molecular building blocks such as benzene rings, amidines, guanidines, and amino groups have been combined in a systematic way to generate ligand candidates for HIV-1 TAR RNA. Ranking of the resulting compounds was achieved in a fluorimetric Tat-TAR competition assay. Although simple molecules such as phenylguanidine are inactive, few iteration steps led to a set of ligands with IC50 values ranging from 40 to 150 mu M. 1,7-Diaminoisoquinoline 17 and 2,4,6-triaminoquinazoline 22 have been further characterized by NMR titrations with TAR RNA. Compound 22 is bound to TAR at two high affinity sites and shows slow exchange between the free ligand and the RNA complex. These results encourage investigations of dimeric ligands built from two copies of compound 22 or related heterocycles. (C) 2014 Elsevier Ltd. All rights reserved.